Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin’s Lymphomas
05-Dec-2014
- Denmark
“With this study we are expanding the scope of the daratumumab development program, beyond multiple myeloma, into NHL, another disease area where new treatment options are needed, and where daratumumab has shown anti-tumor activity in pre-clinical disease models,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Fibril
Go to page
Joseph_Toynbee
Go to page
Biotechnology
Go to page
Equateq Facility Certified for GMP Pharma Production in Scotland
Go to page
Ablynx appoints Dr. Andreas Menrad as Chief Scientific Officer
Go to page
German_Sims_Woodhead
Go to page
Does Decrease in Scientific Papers Provide Evidence of Scientist Shortage? - Science Watch Study Shows United States Loses Dominant Share of World Science
Go to page
Kuros receives orphan drug designation for a novel fusion protein for the treatment of solitary bone cysts
Go to page
Fifth_disease
Go to page